OSI Pharmaceuticals Receives Allowance of U.S. Patent for Its c-Kit / KDR Compound, OSI-930.MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (NASDAQ NASDAQin full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : OSIP) announced today that its patent application covering claims for its lead c-Kit/KDR compound, OSI-930, has received Notice of Allowance by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property . The resulting patent will cover the compound, compositions containing the compound, and methods of treating cancers with the compound. The issuance of this patent provides protection of OSI-930 until 2024. About OSI-930 OSI-930 is a potent tyrosine kinase inhibitor Noun 1. tyrosine kinase inhibitor - a drug used in cases of chronic myeloid leukemia medicament, medication, medicinal drug, medicine - (medicine) something that treats or prevents or alleviates the symptoms of disease that blocks cellular signaling through the receptor tyrosine kinases, c-kit and vascular epidermal growth factor receptor This article is about a cell suface receptor. For estimated measure of kidney function (eGFR), see Glomerular filtration rate. The epidermal growth factor receptor (VEGFR VEGFR Vascular Endothelial Growth Factor Receptor , also known as KDR). OSI-930, in addition to inhibiting VEGFR, is also equally active against both mutant and wild type c-kit in cellular systems. This compound also has activity in multiple tumor models that are thought to be dependent upon angiogenesis (the process of blood vessel growth). Combining the inhibition of growth and survival pathways with antiangiogenic an·ti·an·gi·o·gen·ic adj. Inhibiting the growth of blood vessels. antiangiogenic activity is designed to translate into a broad range of clinical activity. OSI-930 originated from the Company's research program and is being evaluated in a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I . A second agent from the Company's c-kit/KDR program, OSI-817, is currently being evaluated in pre-clinical toxicology experiments prior to entry into the clinic. About OSI Pharmaceuticals OSI Pharmaceuticals is a leading biotechnology company primarily focused on the discovery, development and commercialization of high-quality pharmaceutical products that extend life or improve the quality of life for cancer and diabetes patients worldwide. OSI's primary business remains oncology, but the Company has a second business interest in the area of diabetes through its subsidiary, Prosidion Limited, based in the United Kingdom. Tarceva(TM), OSI's flagship product, is the first drug discovered and developed by OSI to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. and pancreatic cancer. OSI exclusively markets Novantrone(R) (mitoxantrone concentrate for injection) for the approved oncology indications and markets Gelclair(R) for the relief of pain associated with oral mucositis. For additional information about the company, please visit http://www.osip.com. This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of clinical trials, the FDA review process and other governmental regulation, OSI's and its collaborators' abilities to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion